Company intelligence / Profile preview

Legacy-Xspire

Ridgeland, Mississippi, United States

Ownership: Private
Development stage: Other

Overview

Legacy-Xspire managed the commercialization of several niche, FDA-approved branded and generic prescription drugs primarily in pain management, cardiovascular, and ENT therapeutic areas. Its commercial portfolio was partially acquired by Blue Water Biotech in 2023, including assets with demonstrated efficacy and safety (e.g., ZONTIVITY clinical Phase 3 results in >13,000 patients).

Therapeutic areas: CardiovascularImmunologyRheumatologyInfectious DiseasesNeurology
Modalities: Small moleculeCombination product
Industry: Biotech

Partnerships

HealthEdge Investment Partners (major investor/acquirer, 2019)[1]Blue Water Biotech (acquired major assets, 2023)[3][4][5][6]

Beyond the preview

Go deeper on Legacy-Xspire.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Legacy-Xspire.

Explore the full profile